{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T08:01:52Z","timestamp":1789200112919,"version":"build-2803163510"},"reference-count":51,"publisher":"Oxford University Press (OUP)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Although voriconazole reached the bedside 10 years ago and became the standard care in the treatment of invasive aspergillosis, reliable clinical breakpoints are still in high demand. Moreover, this has increased due to the recent emergence of azole resistance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Four clinical wild-type and non-wild-type A. fumigatus isolates with voriconazole CLSI MICs in the range of 0.125\u20132 mg\/L were tested in an in vitro pharmacokinetic (PK)\/pharmacodynamic (PD) model. Mouse PK was simulated and in vitro data were compared with in vivo outcome. Human PK was simulated and susceptibility breakpoints and trough levels required for optimal treatment were determined for the CLSI and EUCAST methods after 48 h and the gradient concentration MIC test strip (MTS) method after 24 h using the in vitro PK\/PD relationship and Monte Carlo simulation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The in vitro PK\/PD target (95% CI) associated with 50% of the maximal antifungal activity (EC50) was 28.61 (16.18\u201350.61), close to the in vivo EC50 of 14.67 (9.31\u201321.58) fAUC0\u201324\/CLSI MIC. When human PK was simulated, the EC50 was 24.7 (17.9\u201335.6) fAUC0\u201312\/CLSI MIC and it was associated with 6 week survival in clinical studies of invasive pulmonary aspergillosis. Target attainment rates were \u22645% (0%\u201324%), 42% (16%\u201358%), 68% (54%\u201375%) and \u226579% (73%\u201386%) for isolates with CLSI MICs \u22652, 1, 0.5 and \u22640.25 mg\/L, respectively. A trough\/CLSI MIC ratio of 2 was required for optimal treatment. The susceptible\/intermediate\/resistant breakpoints were determined to be 0.25\/0.5\u20131\/2 mg\/L for CLSI, 0.5\/1\u20132\/4 mg\/L for EUCAST and 0.25\/0.375\u20131\/1.5 mg\/L for MTS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These susceptibility breakpoints and target values for therapeutic drug monitoring could be used to optimize voriconazole therapy against A. fumigatus.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dku023","type":"journal-article","created":{"date-parts":[[2014,2,18]],"date-time":"2014-02-18T22:03:48Z","timestamp":1392761028000},"page":"1611-1619","source":"Crossref","is-referenced-by-count":31,"title":["Susceptibility breakpoints and target values for therapeutic drug monitoring of voriconazole and\n                    <i>Aspergillus fumigatus<\/i>\n                    in an\n                    <i>in vitro<\/i>\n                    pharmacokinetic\/pharmacodynamic model"],"prefix":"10.1093","volume":"69","author":[{"given":"Maria","family":"Siopi","sequence":"first","affiliation":[{"name":"National and Kapodistrian University of Athens 1 \u00a0 Clinical Microbiology Laboratory, Attikon University Hospital, Medical School , , Athens , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleftheria","family":"Mavridou","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases 2 \u00a0 Transplantation-Oncology Infectious Diseases Program , , Weill Cornell Medical College of Cornell University , New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan W.","family":"Mouton","sequence":"additional","affiliation":[{"name":"Radboud University Medical Centre 3 \u00a0 Department of Medical Microbiology , , Nijmegen , The Netherlands"},{"name":"Erasmus University Medical Center 4 \u00a0 Department of Medical Microbiology and Infectious Diseases , , Rotterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul E.","family":"Verweij","sequence":"additional","affiliation":[{"name":"Radboud University Medical Centre 3 \u00a0 Department of Medical Microbiology , , Nijmegen , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loukia","family":"Zerva","sequence":"additional","affiliation":[{"name":"National and Kapodistrian University of Athens 1 \u00a0 Clinical Microbiology Laboratory, Attikon University Hospital, Medical School , , Athens , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Meletiadis","sequence":"additional","affiliation":[{"name":"National and Kapodistrian University of Athens 1 \u00a0 Clinical Microbiology Laboratory, Attikon University Hospital, Medical School , , Athens , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2014,2,17]]},"reference":[{"key":"2023062716374889400_DKU023C1","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1086\/525258","article-title":"Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America","volume":"46","author":"Walsh","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2023062716374889400_DKU023C2","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis","volume":"347","author":"Herbrecht","year":"2002","journal-title":"N Engl J Med"},{"key":"2023062716374889400_DKU023C3","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.3201\/eid1507.090043","article-title":"Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure","volume":"15","author":"Howard","year":"2009","journal-title":"Emerg Infect Dis"},{"key":"2023062716374889400_DKU023C4","doi-asserted-by":"crossref","first-page":"335","DOI":"10.2217\/fmb.11.4","article-title":"Azole resistance in Aspergillus fumigatus: a new challenge in the management of invasive aspergillosis?","volume":"6","author":"Snelders","year":"2011","journal-title":"Future Microbiol"},{"key":"2023062716374889400_DKU023C5","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1128\/JCM.00854-09","article-title":"Patterns of susceptibility of Aspergillus isolates recovered from patients enrolled in the Transplant-Associated Infection Surveillance Network","volume":"47","author":"Baddley","year":"2009","journal-title":"J Clin Microbiol"},{"key":"2023062716374889400_DKU023C6","doi-asserted-by":"crossref","first-page":"E278","DOI":"10.1111\/1469-0691.12148","article-title":"EUCAST technical note on voriconazole and Aspergillus spp","volume":"19","author":"Hope","year":"2013","journal-title":"Clin Microbiol Infect"},{"key":"2023062716374889400_DKU023C7","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/infdis\/jis372","article-title":"Pharmacodynamics of voriconazole in a dynamic in vitro model of invasive pulmonary aspergillosis: implications for in vitro susceptibility breakpoints","volume":"206","author":"Jeans","year":"2012","journal-title":"J Infect Dis"},{"key":"2023062716374889400_DKU023C8","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1128\/AAC.05959-11","article-title":"Epidemiological cutoff values for azoles and Aspergillus fumigatus based on a novel mathematical approach incorporating cyp51A sequence analysis","volume":"56","author":"Meletiadis","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2023062716374889400_DKU023C9","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1080\/13693780701644140","article-title":"Animal models: an important tool in mycology","volume":"45","author":"Capilla","year":"2007","journal-title":"Med Mycol"},{"key":"2023062716374889400_DKU023C10","first-page":"111","article-title":"Use of an animal model of disseminated candidiasis in the evaluation of antifungal therapy","volume":"118","author":"Andes","year":"2005","journal-title":"Methods Mol Med"},{"key":"2023062716374889400_DKU023C11","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1086\/595846","article-title":"Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry","volume":"48","author":"Neofytos","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2023062716374889400_DKU023C12","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1128\/AAC.01331-12","article-title":"Evaluation of the in vitro activity of voriconazole as predictive of in vivo outcome in a murine Aspergillus fumigatus infection model","volume":"57","author":"Salas","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2023062716374889400_DKU023C13","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1128\/AAC.00705-08","article-title":"Antifungal therapeutic drug monitoring: established and emerging indications","volume":"53","author":"Andes","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2023062716374889400_DKU023C14","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1097\/FTD.0b013e31817b1a95","article-title":"Therapeutic drug monitoring of voriconazole","volume":"30","author":"Bruggemann","year":"2008","journal-title":"Ther Drug Monit"},{"key":"2023062716374889400_DKU023C15","doi-asserted-by":"crossref","first-page":"4782","DOI":"10.1128\/AAC.01083-10","article-title":"Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients","volume":"55","author":"Troke","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2023062716374889400_DKU023C16","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1086\/524669","article-title":"Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes","volume":"46","author":"Pascual","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2023062716374889400_DKU023C17","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1128\/AAC.00662-11","article-title":"Pharmacodynamic effects of simulated standard doses of antifungal drugs against Aspergillus species in a new in vitro pharmacokinetic\/pharmacodynamic model","volume":"56","author":"Meletiadis","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2023062716374889400_DKU023C18","doi-asserted-by":"crossref","first-page":"5321","DOI":"10.1128\/AAC.00549-12","article-title":"In vitro pharmacokinetic\/pharmacodynamic modeling of voriconazole activity against Aspergillus species in a new in vitro dynamic model","volume":"56","author":"Al-Saigh","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2023062716374889400_DKU023C19","doi-asserted-by":"crossref","first-page":"4758","DOI":"10.1128\/AAC.00606-10","article-title":"Impact of cyp51A mutations on the pharmacokinetic and pharmacodynamic properties of voriconazole in a murine model of disseminated aspergillosis","volume":"54","author":"Mavridou","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2023062716374889400_DKU023C20","volume-title":"Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi\u2014Second Edition: Approved Standard M38-A2","author":"Clinical and Laboratory Standards Institute","year":"2008"},{"key":"2023062716374889400_DKU023C21","author":"EUCAST"},{"key":"2023062716374889400_DKU023C22","first-page":"1","article-title":"Determination of voriconazole levels in serum of hematological patents with a microbiological assay","volume":"58","author":"Siopi","year":"2013","journal-title":"B Hel Soc Microbiol"},{"key":"2023062716374889400_DKU023C23","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1128\/AAC.46.8.2546-2553.2002","article-title":"Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens","volume":"46","author":"Purkins","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 1","key":"2023062716374889400_DKU023C24","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1046\/j.1365-2125.2003.01992.x","article-title":"The pharmacokinetics and safety of intravenous voriconazole\u2014a novel wide-spectrum antifungal agent","volume":"56","author":"Purkins","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"2023062716374889400_DKU023C25","volume-title":"VFEND\u00ae (Voriconazole) United States Package Insert","author":"Pfizer Inc","year":"2010"},{"key":"2023062716374889400_DKU023C26","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1128\/JCM.00536-10","article-title":"Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document)","volume":"49","author":"Espinel-Ingroff","year":"2010","journal-title":"J Clin Microbiol"},{"key":"2023062716374889400_DKU023C27","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1002\/cncr.22568","article-title":"Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients","volume":"109","author":"Trifilio","year":"2007","journal-title":"Cancer"},{"key":"2023062716374889400_DKU023C28","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1128\/AAC.01601-08","article-title":"Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect","volume":"53","author":"Warn","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2023062716374889400_DKU023C29","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1128\/AAC.47.10.3165-3169.2003","article-title":"In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model","volume":"47","author":"Andes","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"2023062716374889400_DKU023C30","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.idc.2006.06.007","article-title":"Pharmacokinetics and pharmacodynamics of antifungals","volume":"20","author":"Andes","year":"2006","journal-title":"Infect Dis Clin North Am"},{"key":"2023062716374889400_DKU023C31","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1128\/AAC.50.5.1878-1880.2006","article-title":"Intrapulmonary penetration of voriconazole in patients receiving an oral prophylactic regimen","volume":"50","author":"Capitano","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2023062716374889400_DKU023C32","doi-asserted-by":"crossref","first-page":"4581","DOI":"10.1128\/AAC.00942-13","article-title":"Relationship between trough plasma and epithelial lining fluid concentrations of voriconazole in lung transplant recipients","volume":"57","author":"Heng","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2023062716374889400_DKU023C33","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1128\/AAC.00885-08","article-title":"Concentrations of voriconazole in healthy and inflamed lung in rats","volume":"53","author":"Joukhadar","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2023062716374889400_DKU023C34","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ijantimicag.2008.08.020","article-title":"Free renal levels of voriconazole determined by microdialysis in healthy and Candida sp.-infected Wistar rats","volume":"33","author":"de Araujo","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"2023062716374889400_DKU023C35","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1002\/cncr.23441","article-title":"Changes in causes of death over time after treatment for invasive aspergillosis","volume":"112","author":"Wingard","year":"2008","journal-title":"Cancer"},{"key":"2023062716374889400_DKU023C36","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/jac\/45.5.673","article-title":"Efficacy of voriconazole against invasive pulmonary aspergillosis in a guinea-pig model","volume":"45","author":"Chandrasekar","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"2023062716374889400_DKU023C37","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1128\/AAC.00329-09","article-title":"Combination therapy in treatment of experimental pulmonary aspergillosis: in vitro and in vivo correlations of the concentration- and dose-dependent interactions between anidulafungin and voriconazole by Bliss independence drug interaction analysis","volume":"53","author":"Petraitis","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2023062716374889400_DKU023C38","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1128\/AAC.00315-06","article-title":"Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model","volume":"50","author":"Olson","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2023062716374889400_DKU023C39","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s002800051011","article-title":"Effects of protein binding on the in vitro activity of antitumour acridine derivatives and related anticancer drugs","volume":"45","author":"Finlay","year":"2000","journal-title":"Cancer Chemother Pharmacol"},{"key":"2023062716374889400_DKU023C40","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1124\/dmd.31.6.731","article-title":"The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human","volume":"31","author":"Roffey","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"2023062716374889400_DKU023C41","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1128\/AAC.01433-10","article-title":"Protein binding: do we ever learn?","volume":"55","author":"Zeitlinger","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2023062716374889400_DKU023C42","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/nrd3287","article-title":"The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery","volume":"9","author":"Smith","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"2023062716374889400_DKU023C43","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1128\/AAC.01573-12","article-title":"Inhibitory and fungicidal effects of antifungal drugs against Aspergillus species in the presence of serum","volume":"57","author":"Elefanti","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2023062716374889400_DKU023C44","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1093\/jac\/dkp434","article-title":"In vitro pharmacodynamic models to determine the effect of antibacterial drugs","volume":"65","author":"Gloede","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"2023062716374889400_DKU023C45","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.diagmicrobio.2011.03.002","article-title":"Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria","volume":"70","author":"Pfaller","year":"2011","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2023062716374889400_DKU023C46","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1093\/jac\/dkt075","article-title":"The cdr1B efflux transporter is associated with non-cyp51A-mediated itraconazole resistance in Aspergillus fumigatus","volume":"68","author":"Fraczek","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"2023062716374889400_DKU023C47","doi-asserted-by":"crossref","first-page":"4405","DOI":"10.1128\/AAC.48.11.4405-4413.2004","article-title":"In vitro evolution of itraconazole resistance in Aspergillus fumigatus involves multiple mechanisms of resistance","volume":"48","author":"da Silva Ferreira","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"2023062716374889400_DKU023C48","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1128\/AAC.50.4.1570-1572.2006","article-title":"Voriconazole therapeutic drug monitoring","volume":"50","author":"Smith","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2023062716374889400_DKU023C49","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1093\/jac\/dkm518","article-title":"Activities of voriconazole, itraconazole and amphotericin B in vitro against 590 moulds from 323 patients in the voriconazole Phase III clinical studies","volume":"61","author":"Espinel-Ingroff","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"2023062716374889400_DKU023C50","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1086\/423274","article-title":"Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole","volume":"39","author":"Imhof","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2023062716374889400_DKU023C51","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/myc.12045","article-title":"Growth of Aspergillus in blood cultures: proof of invasive aspergillosis in patients with chronic obstructive pulmonary disease?","volume":"56","author":"Giannella","year":"2013","journal-title":"Mycoses"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/69\/6\/1611\/50723381\/jac_69_6_1611.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/69\/6\/1611\/50723381\/jac_69_6_1611.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T14:27:47Z","timestamp":1687876067000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/69\/6\/1611\/833540"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,17]]},"references-count":51,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2014,2,17]]},"published-print":{"date-parts":[[2014,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dku023","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718281892.793495471","asserted-by":"object"}]},"ISSN":["1460-2091","0305-7453"],"issn-type":[{"value":"1460-2091","type":"electronic"},{"value":"0305-7453","type":"print"}],"subject":[],"published-other":{"date-parts":[[2014,6]]},"published":{"date-parts":[[2014,2,17]]}}}